Zhejiang Huahai Pharmaceutical announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the combination tablet of linagliptin and metformin. This pharmaceutical is mainly used to improve blood sugar control levels in adult patients with type 2 diabetes, with each tablet containing 2.5mg of linagliptin and 850 mg of metformin hydrochloride.
华海药业：获利格列汀二甲双胍片注册证书
Zhejiang Huahai Pharmaceutical: Obtained the registration certificate for linagliptin and metformin hydrochloride tablets
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated